( NYSE:VRX,Toronto:VRX )

News from valeant pharmaceuticals international, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Mar 16, 2015, 08:00 ET Valeant And Salix Agree On Amended Terms To Merger Agreement

- $173 PER SHARE CASH OFFER THROUGH APRIL 7TH - TRANSACTION EXPECTED TO CLOSE APRIL 1ST  Valeant Pharmaceuticals International,...


Mar 13, 2015, 15:48 ET Valeant Announces HSR Clearance For Salix Acquisition

 Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant" or the "Company") announced today that it has received early...


Mar 13, 2015, 09:26 ET Valeant Announces Pricing Of Private Offering Of Senior Notes

 Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant" or the "Company") announced today that VRX Escrow Corp., a newly...


Mar 11, 2015, 18:10 ET Valeant Comments On Endo Offer To Acquire Salix

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today issued the below statement in response to Endo International PLC's...


Mar 09, 2015, 16:40 ET Valeant Announces Launch Of Private Offering Of Senior Notes

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announced today that VRX Escrow Corp., a newly formed wholly owned Canadian...


Feb 25, 2015, 08:00 ET PROVENGE® (sipuleucel-T) Demonstrates Sustained Immune Response Two Years after Treatment in Biochemically-Recurrent Prostate Cancer

 Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced the presentation of new long-term, preliminary results...


Feb 22, 2015, 16:00 ET Valeant To Acquire Salix Pharmaceuticals For $158.00 Per Share In Cash

- Salix is the Leader in the Growing U.S. Gastrointestinal Market - Transaction Creates a New Specialty Platform for Growth -...


Feb 22, 2015, 16:00 ET Valeant Pharmaceuticals Reports Fourth Quarter And Full Year 2014 Financial Results

2014 Fourth Quarter Results - Total revenue $2.3 billion; an increase of 10% over the prior year despite negative foreign exchange impact...


Feb 10, 2015, 17:15 ET Valeant Pharmaceuticals Announces Expiration Of Bid Deadline In Connection With Agreement To Acquire Assets From Dendreon

 Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that they have been advised by Dendreon Corporation that no...


Feb 05, 2015, 10:30 ET Valeant Enters Into Amended Agreement To Remain Lead Bidder In Acquisition Of Dendreon And Its Leading Immunotherapy Treatment, PROVENGE® (sipuleucel-T)

 Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that yesterday it entered into an amended and restated...


Feb 05, 2015, 08:00 ET Valeant Pharmaceuticals To Announce 2014 Fourth Quarter And Full Year Results On February 24, 2015

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it will host a conference call and a live Internet webcast...


Jan 29, 2015, 21:00 ET Valeant Selected As Lead Bidder To Acquire Dendreon And Its Leading Immunotherapy Treatment, PROVENGE® (sipuleucel-T)

 Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it has entered into a "stalking horse" asset purchase...


Jan 20, 2015, 08:00 ET Bausch + Lomb Introduces New Software and Advanced OCT Imaging System for VICTUS® Femtosecond Laser Platform

 Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that its wholly owned subsidiary, Bausch + Lomb, has...


Jan 15, 2015, 17:00 ET Valeant Announces Pricing Of Private Offering Of Senior Notes

 Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announced today that it has priced its previously announced offering of...


Jan 15, 2015, 17:00 ET Valeant Announces Redemption of All of the Approximately $500 Million Aggregate Principal Amount of its Outstanding 6.875% Senior Notes due 2018

 Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that its wholly owned subsidiary, Valeant Pharmaceuticals...


Jan 15, 2015, 09:15 ET Valeant Announces Launch of Private Offering of Senior Notes

 Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announced today that it has launched an offering of approximately $1.0...


Jan 06, 2015, 10:15 ET Valeant Pharmaceuticals To Present At The J.P. Morgan 2015 Healthcare Conference

 Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that members of its senior management team will make a...


Dec 15, 2014, 16:30 ET Valeant Pharmaceuticals To Hold Conference Call To Announce 2015 Financial Guidance

 Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it will host a conference call and a live Internet...


Nov 28, 2014, 17:00 ET Valeant Announces Redemption of US$445.0 Million Aggregate Principal Amount of its Outstanding 6.875% Senior Notes due 2018

 Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that its wholly owned subsidiary, Valeant Pharmaceuticals...


Nov 25, 2014, 08:00 ET Valeant Pharmaceuticals Announces FDA Approval Of ONEXTON™ Gel For The Treatment Of Acne Vulgaris

 Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that it has received approval from the Food and Drug...